Allergan, Mylan Launch Generics of Janssen’s Invega
Allergan and Mylan have launched respective generic versions of Janssen’s Invega (paliperidone extended-release tablets) in the US. Invega extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). Mylan launched extended-release tablets of 1.5 mg, 3 mg, 6 mg, and 9 mg.
For the 12 months ended July 31, 2015, Invega had total US brand sales of approximately $612 million, according to IMS Health data, and as reported by Allergan.
